The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data.
M. H. Moehler
Honoraria - Bayer
C. C. Schimanski
Honoraria - Bayer
Research Funding - Bayer
S. Kanzler
No relevant relationships to disclose
M. A. Woerns
Honoraria - Bayer
U. Denzer
No relevant relationships to disclose
F. T. Kolligs
No relevant relationships to disclose
M. P. Ebert
No relevant relationships to disclose
A. Distelrath
No relevant relationships to disclose
M. Geissler
No relevant relationships to disclose
S. Zeuzem
No relevant relationships to disclose
F. Lammert
No relevant relationships to disclose
A. W. Lohse
No relevant relationships to disclose
M. M. Dollinger
Consultant or Advisory Role - Bayer
Honoraria - Bayer
U. Lindig
No relevant relationships to disclose
E. M. Duerr
No relevant relationships to disclose
N. Lubomierski
No relevant relationships to disclose
S. Zimmermann
No relevant relationships to disclose
M. Kabisch
No relevant relationships to disclose
S. Schadmann-Fischer
No relevant relationships to disclose
P. R. Galle
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Bayer